Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Notes Payables (2017 - 2026)

Ekso Bionics Holdings has reported Notes Payables over the past 11 years, most recently at $1.2 million for Q4 2025.

  • On a quarterly basis, Notes Payables changed 0.0% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 0.0% change, with the full-year FY2025 number at $1.2 million, changed 0.0% from a year prior.
  • Notes Payables reached $1.2 million in Q4 2025 per EKSO's latest filing, roughly flat from $1.2 million in the prior quarter.
  • The five-year high for Notes Payables was $2.9 million in Q2 2023, with the low at $814000.0 in Q1 2021.
  • The 5-year median for Notes Payables is $1.2 million (2023), against an average of $1.5 million.
  • Peak YoY movement for Notes Payables: crashed 62.49% in 2021, then changed 0.0% in 2024.
  • Tracing EKSO's Notes Payables over 5 years: stood at $814000.0 in 2021, then surged by 183.78% to $2.3 million in 2022, then tumbled by 45.89% to $1.2 million in 2023, then changed by 0.0% to $1.2 million in 2024, then changed by 0.0% to $1.2 million in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $1.2 million, $1.2 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.